Phase II Open-Label Study of Weekly Taxoprexin (DHA-Paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-Choroidal Melanoma.

Trial Profile

Phase II Open-Label Study of Weekly Taxoprexin (DHA-Paclitaxel) Injection as First Line Treatment of Patients With Metastatic Non-Choroidal Melanoma.

Completed
Phase of Trial: Phase II

Latest Information Update: 20 Oct 2009

At a glance

  • Drugs DHA-paclitaxel (Primary)
  • Indications Malignant melanoma
  • Focus Therapeutic Use
  • Sponsors Luitpold Pharmaceuticals
  • Most Recent Events

    • 14 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 14 Jan 2009 Status changed from active, no longer recruiting to completed, as reported by ClinicalTrials.gov.
    • 18 Jan 2007 Status changed from recruiting to in progress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top